GlassScriptPhysician profile
Brianna N Dillon
NPI 1063870749
$4,339.87
in general payments reported to CMS, 2019-2025
30 companies · $755 in 2025
The $755 reported for 2025 was more than what 79% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,119 · 2022: $528 · 2023: $928 · 2024: $1,010 · 2025: $755.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,693.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,693.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,113.90 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $542.55 | 2021-2025 | |
| Lilly USA, LLC | $514.05 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $393.42 | 2021-2025 | Airsupra, Farxiga |
| Amgen INC. | $299.72 | 2021-2025 | Otezla, Repatha, Otezla |
| Otsuka America Pharmaceutical, INC. | $256.82 | 2021-2025 | Rexulti |
| Pfizer INC. | $157.58 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $137.89 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $108.89 | 2025 | |
| Exact Sciences Corporation | $88.12 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Cardiovascular Systems INC. | $78.88 | 2021 | |
| Glaxosmithkline, LLC. | $76.59 | 2021-2023 | Shingrix, Arexvy |
| Amarin Pharma, INC. | $72.10 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $64.32 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $54.14 | 2025 | Caplyta |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Antares Pharma, INC. | $40.43 | 2022-2023 | Nocdurna, Tlando, Xyosted |
| Eisai INC. | $38.61 | 2021-2024 | |
| Currax Pharmaceuticals LLC | $35.51 | 2023 | Contrave, Onzetra Xsail |
| Astellas Pharma US INC | $34.69 | 2024 | Veozah |
| Medtronic, INC. | $32.87 | 2023 | Intellis Adaptivestim |
| Sanofi-Aventis U.S. LLC | $31.03 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $23.68 | 2022 | |
| Xeris Pharmaceuticals, INC. | $21.11 | 2023 | Keveyis |
| Bayer Healthcare Pharmaceuticals INC. | $19.31 | 2021 | |
| Axsome Therapeutics, INC. | $19.26 | 2025 | Auvelity |
| Genentech USA, INC. | $18.73 | 2021 | |
| Sumitomo Pharma America, INC. | $18.06 | 2024 | Gemtesa |
| Janssen Pharmaceuticals, INC | $17.95 | 2023 | Xarelto |
| Ultragenyx Pharmaceutical INC. | $15.15 | 2023 | Crysvita |
| Kowa Pharmaceuticals America, INC. | $14.51 | 2023 | Seglentis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brianna Dillon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.